Danaher Corporation $DHR Stock: Salem Investment Counselors Inc. Increases Holdings

Salem Investment Counselors Inc. lifted its stake in shares of Danaher Corporation (NYSE:DHR) by 1,462.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 8,939 shares of the conglomerate’s stock after acquiring an additional 8,367 shares during the quarter. Salem Investment Counselors Inc.’s holdings in Danaher were worth $1,980,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of DHR. Keystone Financial Group Inc. acquired a new stake in Danaher during the 3rd quarter worth about $640,000. Signal Advisors Wealth LLC purchased a new stake in Danaher during the third quarter valued at about $1,459,000. GEM Asset Management LLC acquired a new position in shares of Danaher in the third quarter worth about $937,000. Copeland Capital Management LLC acquired a new position in shares of Danaher in the third quarter worth about $773,000. Finally, Foster Group Inc. purchased a new position in shares of Danaher in the third quarter worth approximately $716,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.8%

Shares of NYSE DHR opened at $224.65 on Thursday. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The firm has a market capitalization of $157.93 billion, a PE ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $212.92 and a two-hundred day moving average price of $195.39.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.77 EPS. As a group, analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DHR shares. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Guggenheim upped their price target on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. The Goldman Sachs Group raised their price objective on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Wells Fargo & Company lowered their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Finally, TD Cowen lifted their price objective on shares of Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.